EVEREST MED (01952) releases annual performance: revenue of 1.707 billion, a year-on-year increase of 141.51%; sales of Nephrocaps drive strong growth.

Everest Med (01952) announced its annual performance as of December 31, 2025. The Group's revenue reached RMB 1.707 billion, a year-on-year increase of 141.51%; the shareholders' net loss was RMB 298 million; R&D expenses were RMB 511 million; and gross profit was RMB 1.182 billion, a year-on-year increase of 124.32%. The increase in revenue was mainly due to the continued growth in sales of Nuvokan in commercialized markets. In the Chinese market, the inclusion of Nuvokan in the National Reimbursement Drug List ("NRDL") was a key driver of growth, resulting in a significant increase in Nuvokan revenue for the year ended December 31, 2025. In markets outside of China, Nuvokan has successfully launched in Taiwan and Korea, achieving important milestones, with sales continuing to rise in other Asian markets. Additionally, Velsipity has been successfully launched in the Singapore market. These achievements highlight the Group's progress in expanding its presence in Asia and improving patient access to medication. The company has successfully achieved multiple R&D milestones during the year and has been actively optimizing its R&D strategy to accelerate the development of its intracellular CAR-T and mRNA platforms, moving towards the next stage of research and clinical preparation, and further unlocking the value of EVER001 (heptotinib). Furthermore, with its excellent clinical development capabilities, the company is enriching its late-stage product pipeline through strategic partnerships and authorized projects.